CR Scherzer

Genetic screening and metabolomics identify glial adenosine metabolism as a therapeutic target in Parkinson’s disease

Neuronal α-synucleinopathies, including Parkinson’s disease (PD) and dementia with Lewy bodies (DLB), lack disease-modifying therapies. We developed a Drosophila model for identifying novel glial-based therapeutic targets for α-synucleinopathies. In this model, human α-synuclein is expressed in neurons and individual g...